BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ruxolitinib (Jakafi) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ruxolitinib (Jakafi)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03681561-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT03681561)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2.\nStudy: Nivolumab With Ruxoli
 tinib in Relapsed or Refractory Classical Hodgkin Lymphoma\nEstimated prim
 ary completion: November 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03681561
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06199427-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20261121
DTEND;VALUE=DATE:20261122
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06199427)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: PTCy and and Ruxolitini
 b for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regim
 en in Patients With Inborn Errors of Immunity\nEstimated primary completio
 n: 21 November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06199427
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03286530-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT03286530)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Ruxolitinib + Allogenei
 c Stem Cell Transplantation in AML\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-ja
 kafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03286530
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987058-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06987058)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: RVU120 Rollover Study\n
 Estimated primary completion: December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06987058
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04041050-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT04041050)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: A Study Evaluating Safe
 ty and Tolerability\, and Pharmacokinetics of Navitoclax Monotherapy and i
 n Combination With Ruxolitinib in Participants With Myeloproliferative Neo
 plasm\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04041050
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04454658-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT04454658)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1\, Myelofibrosis.\nStudy: Safety 
 and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination Wit
 h Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants 
 With Myelofibrosis\nEstimated primary completion: January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04454658
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714072-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT05714072)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1\, Myelofibrosis.\nStudy: A Study
  of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelo
 fibrosis\nEstimated primary completion: January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05714072
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06345495-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06345495)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: High Do
 se Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis P
 atients With Splenomegaly\nEstimated primary completion: 1 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0634549
 5
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05371964-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT05371964)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1\, Myelofibrosis.\nStudy: A Study
  to Evaluate the Safety\, Pharmacokinetics\, Pharmacodynamics and Clinical
  Activity of Imetelstat in Combination With Ruxolitinib in Participants Wi
 th Myelofibrosis\nEstimated primary completion: February 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05371964
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03069326-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT03069326)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: A Clini
 cal Study to Test the Effects of Ruxolitinib And Thalidomide Combination f
 or Patients With Myelofibrosis\nEstimated primary completion: February 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT030
 69326
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06225310-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT06225310)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: A Trial of Selinexor\, 
 Ruxolitinib and Methylprednisolone\nEstimated primary completion: 1 April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jak
 afi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06225310
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04279847-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT04279847)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1\, Myelofibrosis.\nStudy: Safety 
 and Tolerability Study of INCB057643 in Participants With Myelofibrosis an
 d Other Advanced Myeloid Neoplasms\nEstimated primary completion: 30 April
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-ja
 kafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04279847
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05423691-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT05423691)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1\, Myelofibrosis.\nStudy: Leading
  in MPNs Beyond Ruxolitinib in Combo With T-Regs\nEstimated primary comple
 tion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05423691
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04176198-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT04176198)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: A Stu
 dy of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis\nEstimated 
 primary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04176198
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05762640-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT05762640)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Ruxolitinib as First Li
 ne Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)\nEstim
 ated primary completion: May 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05762640
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120140-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06120140)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Enhanced Dermatological
  Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (E
 GRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Am
 ivantamab Plus Lazertinib\nEstimated primary completion: 31 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06120140
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008275-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT06008275)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: Neratinib in Combinatio
 n With Ruxolitinib in Patients With mTNBC\nEstimated primary completion: J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib
 -jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06008275
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02494882-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT02494882)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: Adding Ruxolitinib to a
  Combination of Dasatinib Plus Dexamethasone in Remission Induction Therap
 y in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic 
 Leukemia Patients Aged 40 Years or Older\nEstimated primary completion: Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-
 jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT02494882
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05980806-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT05980806)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: A Study
  of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibro
 sis and Moderate Thrombocytopenia\nEstimated primary completion: June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0598
 0806
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340723-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07340723)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host 
 Disease )\nEstimated primary completion: 1 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07340723
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06936566-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06936566)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: MAGIC Ruxolitinib for aGVHD\nEstimated primary completion: 1 June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 36566
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07249346-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07249346)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tac
 rolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in My
 eloablative Allogeneic Peripheral Blood Stem Cell Transplantation\nEstimat
 ed primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07249346
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07032727-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07032727)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Olutasidenib Combined W
 ith Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Mal
 ignancies Harboring Activated Signaling Pathway Mutations\nEstimated prima
 ry completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07032727
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951971-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ruxolitinib (Jakafi): Phase 2/3 readout est. (NCT06951971)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2/3.\nStudy: Dose-modified Emapalu
 mab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
 \nEstimated primary completion: 1 June 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06951971
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366801-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Ruxolitinib (Jakafi): Phase 2/3 readout est. (NCT07366801)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2/3\, Graft-versus-Host Disease.\n
 Study: Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted He
 matopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After All
 ogeneic Hematopoietic Stem Cell Transplantation Among Children With Hemato
 logic Malignancies\nEstimated primary completion: 1 June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07366801
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06150157-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT06150157)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: A Study of JNJ-88549968
  for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neopl
 asms\nEstimated primary completion: 14 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06150157
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644211-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT04644211)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Polycythemia Vera.\nStudy: Rux
 olitinib in Thrombocythemia and Polycythemia Vera\nEstimated primary compl
 etion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rux
 olitinib-jakafi#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04644211
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05592015-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT05592015)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Ruxolitinib for the Tre
 atment of T-Cell Large Granular Lymphocytic Leukemia\nEstimated primary co
 mpletion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05592015
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05010005-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT05010005)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: A Study of Ruxolitinib 
 and Duvelisib in People With Lymphoma\nEstimated primary completion: Augus
 t 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-j
 akafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05010005
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04061421-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT04061421)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2.\nStudy: Active Myeloid Target
  Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABN
 L-MARRO)\nEstimated primary completion: August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04061421
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06008808-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270908
DTEND;VALUE=DATE:20270909
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT06008808)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1\, Graft-versus-Host Disease.\nSt
 udy: Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis 
 of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Re
 plete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation\n
 Estimated primary completion: 8 September 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06008808
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184853-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270925
DTEND;VALUE=DATE:20270926
SUMMARY:Ruxolitinib (Jakafi): Phase na readout est. (NCT07184853)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase na.\nStudy: Ruxolitinib Plus Etane
 rcept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD\nEstimated p
 rimary completion: 25 September 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07184853
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796620-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT07796620)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2.\nStudy: Sirolimus+Ruxolitinib
 +Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Hapl
 o-HSCT Who Are Intolerant to CNI\nEstimated primary completion: 30 Septemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-
 jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07796620
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955940-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT02955940)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: An Open-Label Study to 
 Enable Continued Treatment Access for Subjects Previously Enrolled in Stud
 ies of Ruxolitinib\nEstimated primary completion: 30 September 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT02955940
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06909136-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT06909136)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: A Stu
 dy to Evaluate Safety \, Efficacy and Pharmacokinetics of WJ01024 Tablets 
 Combined With Ruxolitinib in Patients With Myelofibrosis\nEstimated primar
 y completion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06909136
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07356245-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07356245)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cel
 l Lymphoma\nEstimated primary completion: 31 October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07356245
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02974647-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT02974647)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Study of Ruxolitinib in
  Relapsed or Refractory T or NK Cell Lymphoma\nEstimated primary completio
 n: November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rux
 olitinib-jakafi#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02974647
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05098210-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT05098210)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: Personalized Neo-Antige
 n Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma\, Hormone Re
 ceptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage
  III-IV Non-Small Cell Lung Cancer\nEstimated primary completion: 1 Novemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-
 jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05098210
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06756061-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06756061)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids C
 oncurrently to Steroids Alone as Initial Treatment In Patients Diagnosed W
 ith Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Sev
 erity\nEstimated primary completion: 1 November 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06756061
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04282187-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271111
DTEND;VALUE=DATE:20271112
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT04282187)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: Decitab
 ine With Ruxolitinib\, Fedratinib or Pacritinib for the Treatment of Accel
 erated/Blast Phase Myeloproliferative Neoplasms\nEstimated primary complet
 ion: 11 November 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04282187
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219576-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT07219576)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2.\nStudy: Retifanlimab and Ruxo
 litinib In Solid Malignancies\nEstimated primary completion: December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0721
 9576
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02577926-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT02577926)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Polycythemia Vera.\nStudy: The
  Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk
  Essential Thrombocythemia\nEstimated primary completion: December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0257792
 6
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05398809-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT05398809)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Evaluate the Efficacy a
 nd Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Poly
 endocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopec
 ia Areata\nEstimated primary completion: 1 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05398809
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07278856-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271210
DTEND;VALUE=DATE:20271211
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT07278856)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: Ruxolitinib in Combinat
 ion With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicul
 ar Helper Cell Lymphomas\nEstimated primary completion: 10 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072788
 56
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07238712-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271210
DTEND;VALUE=DATE:20271211
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07238712)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Optimization of Post-tr
 ansplantation Benadamustine and Cyclophosphamide in Patients With High-ris
 k Myeloid Malignancies and a Partially Mismatched Donor\nEstimated primary
  completion: 10 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07238712
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07576010-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT07576010)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1\, Graft-versus-Host Disease.\nSt
 udy: Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II
  Acute Graft-versus-Host Disease\nEstimated primary completion: 30 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-j
 akafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07576010
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509749-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07509749)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)\nEs
 timated primary completion: 30 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07509749
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03874052-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT03874052)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: Ruxolitinib in Combinat
 ion With Venetoclax With and Without Azacitidine in Treating Patients With
  Relapsed or Refractory Acute Myeloid Leukemia\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03874052
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548983-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT07548983)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: Ruxolitinib With Azacit
 idine Maintenance for the Treatment of Patients With Acute Myeloid Leukemi
 a Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07548983
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07588945-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ruxolitinib (Jakafi): Phase 3 readout est. (NCT07588945)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 3.\nStudy: daGOAT-Guided Preventio
 n of Severe aGVHD After Allo-HSCT\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-
 jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07588945
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364319-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ruxolitinib (Jakafi): Phase 4 readout est. (NCT06364319)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 4.\nStudy: Efficacy and Safety of 
 Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD\nEstimated pr
 imary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06364319
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06773195-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT06773195)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: A Stu
 dy of Ruxolitinib in Combination With Ulixertinib in People With Myelofibr
 osis\nEstimated primary completion: January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06773195
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283822-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07283822)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Amping up With PemJAK\n
 Estimated primary completion: January 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07283822
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101588-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Ruxolitinib (Jakafi): Phase 4 readout est. (NCT07101588)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 4.\nStudy: Ruxolitinib-Decitabine 
 Intensified Conditioning Regimen for AML: A Randomized Trial\nEstimated pr
 imary completion: 1 January 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07101588
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973668-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06973668)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: A Randomized Study to Compare Post-transplant Cyclophosphamide\, Siro
 limus\, Ruxolitinib and Post-transplant Cyclophosphamide\, Sirolimus\, Myc
 ophenolate Mofetil to Prevent Graft Versus Host Disease\nEstimated primary
  completion: 31 January 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06973668
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05037760-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT05037760)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: A Study
  of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofib
 rosis\nEstimated primary completion: 28 February 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05037760
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05936359-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT05936359)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: A Study to Evaluate INC
 A033989 Administered as a Monotherapy or in Combination With Ruxolitinib i
 n Participants With Myeloproliferative Neoplasms\nEstimated primary comple
 tion: 29 February 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05936359
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05870475-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT05870475)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Polycythemia Vera.\nStudy: Peg
 ylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydro
 xyurea-resistant/Intolerant PV\nEstimated primary completion: 31 March 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058
 70475
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05088356-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT05088356)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: Reduced Intensity Allog
 eneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft\nEs
 timated primary completion: May 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05088356
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131059-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280510
DTEND;VALUE=DATE:20280511
SUMMARY:Ruxolitinib (Jakafi): Phase na readout est. (NCT07131059)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase na.\nStudy: MRD-positive AML Clini
 cal Study\nEstimated primary completion: 10 May 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07131059
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616155-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT06616155)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2.\nStudy: Ruxolitinib and Enzal
 utamide for the Treatment of Metastatic Castration-Resistant Prostate Canc
 er\nEstimated primary completion: June 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06616155
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859424-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06859424)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: A Platf
 orm Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-V
 ersus-Host Disease Prophylaxis in Patients With Hematologic Malignancies U
 ndergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplant
 ation\nEstimated primary completion: June 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06859424
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06536166-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280610
DTEND;VALUE=DATE:20280611
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06536166)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Ruxolitinib Treatment i
 n Inclusion Body Myositis\nEstimated primary completion: 10 June 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06536166
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07025538-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280622
DTEND;VALUE=DATE:20280623
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT07025538)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1\, Graft-versus-Host Disease.\nSt
 udy: Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Vers
 us Host Disease After Allogeneic Hematopoietic Cell Transplantation\nEstim
 ated primary completion: 22 June 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07025538
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07424222-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT07424222)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: Ruxolitinib for Immune 
 Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome 
 (RISE)\nEstimated primary completion: 1 July 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07424222
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05622318-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280708
DTEND;VALUE=DATE:20280709
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT05622318)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus
 -Host Disease (GVHD) Prophylaxis\nEstimated primary completion: 8 July 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT056
 22318
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085039-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07085039)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Ruxolitinib in Previous
 ly Treated Idiopathic Multicentric Castleman Disease\nEstimated primary co
 mpletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07085039
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04817007-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT04817007)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: A Stu
 dy to Assess the Safety and Tolerability of BMS-986158 Alone and in Combin
 ation With Either Ruxolitinib or Fedratinib in Participants With Blood Can
 cer (Myelofibrosis)\nEstimated primary completion: 31 August 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04817007
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02131584-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT02131584)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Ruxolitinib Phosphate i
 n Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia\nEstimate
 d primary completion: 30 September 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT02131584
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913672-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20281027
DTEND;VALUE=DATE:20281028
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT07913672)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1\, Graft-versus-Host Disease.\nSt
 udy: A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host
  Disease (GVHD)\nEstimated primary completion: 27 October 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07913672
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06034002-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20281029
DTEND;VALUE=DATE:20281030
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT06034002)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: A Study to Evaluate INC
 A033989 Administered as a Monotherapy or in Combination With Ruxolitinib i
 n Participants With Myeloproliferative Neoplasms\nEstimated primary comple
 tion: 29 October 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06034002
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04116502-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Ruxolitinib (Jakafi): Phase 3 readout est. (NCT04116502)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 3\, Polycythemia Vera.\nStudy: MIT
 HRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line T
 herapy in High Risk Polycythemia Vera\nEstimated primary completion: 31 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitin
 ib-jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04116502
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252050-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20281119
DTEND;VALUE=DATE:20281120
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT07252050)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2.\nStudy: Ruxolitinib-Enhanced 
 Haplo HCT for Children and Young Adults With Sickle Cell Disease\nEstimate
 d primary completion: 19 November 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07252050
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06660355-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06660355)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Sys
 temic Therapy\nEstimated primary completion: December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06660355
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734077-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT07734077)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: Revum
 enib in Patients With Myelofibrosis\nEstimated primary completion: 1 Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib
 -jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07734077
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03017820-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT03017820)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: A Vaccine (VSV-hIFNβ-N
 IS) With or Without Cyclophosphamide and Combinations of Ipilimumab\, Nivo
 lumab\, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma
 \, Acute Myeloid Leukemia or Lymphoma\nEstimated primary completion: 31 De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxoliti
 nib-jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT03017820
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508463-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT06508463)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: Intravenous Vesicular S
 tomatitis Virus in Patients With Peripheral T-cell Lymphoma\nEstimated pri
 mary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06508463
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06160791-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06160791)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Ruxolitinib With De-Int
 ensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (H
 LH)\nEstimated primary completion: 31 December 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06160791
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07359859-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07359859)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in Pe
 ople With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
 \nEstimated primary completion: January 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07359859
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06233110-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT06233110)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1\, Graft-versus-Host Disease.\nSt
 udy: Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD\nEstimated
  primary completion: 1 January 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06233110
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311746-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT07311746)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2.\nStudy: Phase Ib/II Trial of 
 Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-c
 ell Prolymphocytic Leukemia\nEstimated primary completion: 31 January 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0731
 1746
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03801434-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT03801434)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Ruxolitinib in Treating
  Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorder
 s\nEstimated primary completion: February 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03801434
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840456-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07840456)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Safety and Efficacy of 
 Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab
  - The Phase 2 InflammaSTOP Trial\nEstimated primary completion: February 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jak
 afi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07840456
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06291987-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT06291987)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: Ivosidenib and Ruxoliti
 nib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Hav
 e an IDH1 Gene Mutation\nEstimated primary completion: May 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06291987
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06327100-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT06327100)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: Open 
 Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosi
 s (PMF)\, Post-Polycythemia Vera Myelofibrosis (Post-PV MF)\, or Post-Esse
 ntial Thrombocytosis Myelofibrosis (Post-ET MF)\nEstimated primary complet
 ion: 1 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxo
 litinib-jakafi#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06327100
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824103-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290510
DTEND;VALUE=DATE:20290511
SUMMARY:Ruxolitinib (Jakafi): Phase 4 readout est. (NCT06824103)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 4.\nStudy: Study of Efficacy and S
 afety of Ruxolitinib in Chinese Participants With Corticosteroid-refractor
 y Chronic Graft vs. Host Disease\nEstimated primary completion: 10 May 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 24103
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464951-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290514
DTEND;VALUE=DATE:20290515
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT07464951)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: CART123 Cells With or W
 ithout Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia\nEstimate
 d primary completion: 14 May 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07464951
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07521046-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT07521046)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1\, Myelofibrosis.\nStudy: Tolerab
 ility of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in 
 Myelofibrosis\nEstimated primary completion: August 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07521046
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498205-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290808
DTEND;VALUE=DATE:20290809
SUMMARY:Ruxolitinib (Jakafi): Phase 4 readout est. (NCT07498205)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 4\, Myelofibrosis.\nStudy: Compari
 ng Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and 
 Low Blood Cell Counts\nEstimated primary completion: 8 August 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07498205
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07643025-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07643025)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft V
 ersus Host Disease (cGvHD)\nEstimated primary completion: November 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0764302
 5
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566897-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT07566897)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: A Phase I Study to Eval
 uate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in 
 Patients With Advanced Solid Tumors\nEstimated primary completion: Decembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-j
 akafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07566897
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06401356-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ruxolitinib (Jakafi): Phase 3 readout est. (NCT06401356)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 3.\nStudy: An Extension Study for 
 Patients Previously Enrolled in Studies With Pelabresib\nEstimated primary
  completion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06401356
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07849231-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT07849231)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: A Study to Evaluate DMR
 -001 in Participants With CALR-mutant Myeloproliferative Neoplasms\nEstima
 ted primary completion: June 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07849231
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05088226-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT05088226)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Ruxolitinib and Chidami
 de Intensified Bu/CY Conditioning Regimen\nEstimated primary completion: 1
  June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitin
 ib-jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05088226
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Ruxolitinib (Jakafi): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 4.\nStudy: Utilization of a Microd
 evice for Psoriasis and Atopic Dermatitis\nEstimated primary completion: 1
  June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitin
 ib-jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07352566
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228624-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07228624)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: Ruxolit
 inib Before\, During and After Hematopoietic Cell Transplant in Older Pati
 ents With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Ne
 oplasm Overlap Syndromes\nEstimated primary completion: 1 September 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072286
 24
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06128070-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20301122
DTEND;VALUE=DATE:20301123
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06128070)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Graft-versus-Host Disease.\nSt
 udy: Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Gr
 aft Versus Host Disease in Pediatric and Young Adult Patients Undergoing A
 llogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia\, Acute
  Lymphoblastic Leukemia\, or Myelodysplastic Syndrome\nEstimated primary c
 ompletion: 22 November 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06128070
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06991101-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06991101)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2.\nStudy: Ruxolitinib With Radiat
 ion and Temozolomide Compared to Radiation and Temozolomide for Newly Diag
 nosed Glioblastoma\nEstimated primary completion: December 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06991101
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615050-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20310117
DTEND;VALUE=DATE:20310118
SUMMARY:Ruxolitinib (Jakafi): Phase 3 readout est. (NCT06615050)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 3\, Graft-versus-Host Disease.\nSt
 udy: A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant
  Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Re
 duced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transpl
 antation (BMT CTN 2203)\nEstimated primary completion: 17 January 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06615050
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128381-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT07128381)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: Phase
  I/II Clinical Trial of Axatilimab\, a CSF1R Monoclonal Antibody\, in Comb
 ination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) a
 nd Chronic Myelomonocytic Leukemia (CMML)\nEstimated primary completion: 3
 1 July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxoliti
 nib-jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07128381
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05745714-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20320201
DTEND;VALUE=DATE:20320202
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT05745714)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2.\nStudy: HEM-iSMART-C: Ruxolit
 inib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Ped
 iatric Patients With Relapsed or Refractory Hematological Malignancies\nEs
 timated primary completion: 1 February 2032. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05745714
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04744116-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT04744116)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1\, Graft-versus-Host Disease.\nSt
 udy: Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ru
 xolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host 
 Disease\nEstimated primary completion: 31 March 2032. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04744116
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02386800-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20320405
DTEND;VALUE=DATE:20320406
SUMMARY:Ruxolitinib (Jakafi): Phase 4 readout est. (NCT02386800)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 4\, Myelofibrosis.\nStudy: CINC424
 A2X01B Rollover Protocol\nEstimated primary completion: 5 April 2032. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT02386800
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297914-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Ruxolitinib (Jakafi): Phase 2/3 readout est. (NCT07297914)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2/3\, Graft-versus-Host Disease.\n
 Study: Framework for Optimizing\, Refining\, and Unifying Management of HS
 CT in Pediatric ALL\nEstimated primary completion: 30 November 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07297914
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06768476-7619@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20450331
DTEND;VALUE=DATE:20450401
SUMMARY:Ruxolitinib (Jakafi): Phase 1 readout est. (NCT06768476)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1.\nStudy: CART123 + Ruxolitinib i
 n Relapsed/Refractory AML\nEstimated primary completion: March 2045. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06768476
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
